- Recognising early warning signs
- Recovery strategies
- Working with sites and CROs
- Lessons learned
- Building partnerships with specialist rare disease centres and referral networks
- Working with centres of excellence to identify patients earlier
- Balancing international recruitment with long-term site relationships
- Strengthening collaboration across investigators, advocacy groups and specialist networks
- Prioritising programmes when resources are limited
- Allocating people across competing studies without creating bottlenecks
- Balancing speed, quality and cost across the portfolio
- Knowing when additional resource will genuinely improve delivery
- Practical approaches to portfolio-level resource planning
- Knowing when to internalise capabilities versus outsource
- Building processes that can scale with the pipeline
- Maintaining oversight as programmes become more complex
- Avoiding operational growing pains
- How CEOs are prioritising programmes
- Balancing scientific ambition with financial reality
- Deciding what to progress and what to stop
- Securing investment in today’s market – are funding opportunities becoming increasingly regional?
- Partnering, licensing and fundraising
- What investors want to hear from leadership teams
